AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- NEW ORLEANS -- Once-daily orforglipron (Foundayo) improved outcomes in adults with type 2 diabetes and inadequate glycemic control, the international ACHIEVE-5 trial showed. In patients already taking background insulin glargine...
Source
MedPage Today
Opens original article in a new tab
(MedPage Today) -- NEW ORLEANS -- Participants with obesity achieved weight loss on par with bariatric surgery and had improvements in two obesity-related conditions while taking a once-weekly investigational triple hormone receptor agonist...
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
(MedPage Today) -- NEW ORLEANS -- Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, the phase III TRANSCEND-T2D-1 trial showed...
(MedPage Today) -- "I realize we're close to beer time here -- promise to at least give you something very scintillating." -- Paul Richardson, MD, of the Dana-Farber Cancer Institute in Boston, before presenting trial results for a novel oral...
